NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors

References

• Rai KR, Jain P. Chronic lymphocytic leukemia (CLL) – then and now. Am J Hematol 2016; 91:330–40; PMID:26690614; https://doi.org/10.1002/ajh.24282
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: Cancer J Clin 2015; 65:5–29; PMID:25559415; https://doi.org/10.3322/caac.21254
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446–56; PMID:18216293; https://doi.org/10.1182/blood-2007-06-093906
   PubMed Web of Science ®Google Scholar
• Santos FP, O'Brien S. Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease? Cancer J 2012; 18:396–403; PMID:23006943; https://doi.org/10.1097/PPO.0b013e31826cda2d/bib>
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Bone ND, Stenson MJ, Novak A, Hedin KE, Kay NE, Ansell SM. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. Mayo Clin Proc 2004; 79:318–25; PMID:15008605; https://doi.org/10.4065/79.3.318
   PubMed Web of Science ®Google Scholar
• Trentin L, Cabrelle A, Facco M, Carollo D, Miorin M, Tosoni A, Pizzo P, Binotto G, Nicolardi L, Zambello R et al. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood 2004; 104:502–8; PMID:15001469; https://doi.org/10.1182/blood-2003-09-3103
   PubMed Web of Science ®Google Scholar
• Wong S, Fulcher D. Chemokine receptor expression in B-cell lymphoproliferative disorders. Leuk Lymphoma 2004; 45:2491–6; PMID:15621766; https://doi.org/10.1080/10428190410001723449/bib>
   PubMed Web of Science ®Google Scholar
• Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG, Gribben JG. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013; 121:1612–21; PMID:23247726; https://doi.org/10.1182/blood-2012-09-457531
   PubMed Web of Science ®Google Scholar
• Nunes C, Wong R, Mason M, Fegan C, Man S, Pepper C. Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin Cancer Res 2012; 18:678–87; PMID:22190592; https://doi.org/10.1158/1078-0432.CCR-11-2630
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, Knolle PA, Thomas RK, von Bergwelt-Baildon M, Debey S et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106:2018–25; PMID:15914560; https://doi.org/10.1182/blood-2005-02-0642
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012; 120:1412–21; PMID:22547582; https://doi.org/10.1182/blood-2012-02-411678
   PubMed Web of Science ®Google Scholar
• Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005; 115:1797–805; PMID:15965501; https://doi.org/10.1172/JCI24176
   PubMed Web of Science ®Google Scholar
• Christopoulos P, Pfeifer D, Bartholome K, Follo M, Timmer J, Fisch P, Veelken H. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood 2011; 117:3836–46; PMID:21270444; https://doi.org/10.1182/blood-2010-07-299321
   PubMed Web of Science ®Google Scholar
• Katrinakis G, Kyriakou D, Papadaki H, Kalokyri I, Markidou F, Eliopoulos GD. Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha. Acta Haematologica 1996; 96:16–23; PMID:8677756; https://doi.org/10.1159/000203709
   PubMed Web of Science ®Google Scholar
• Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984; 63:305–9; PMID:6607080.
   PubMed Web of Science ®Google Scholar
• Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, Gregory SA. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia 2008; 22:998–1006; PMID:18288133; https://doi.org/10.1038/leu.2008.15
   PubMed Web of Science ®Google Scholar
• Ziegler HW, Kay NE, Zarling JM. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981; 27:321–7; PMID:6169660; https://doi.org/10.1002/ijc.2910270310
   PubMed Web of Science ®Google Scholar
• Costello RT, Knoblauch B, Sanchez C, Mercier D, Le Treut T, Sebahoun G. Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia. Immunology 2012; 135:151–7; PMID:22044312; https://doi.org/10.1111/j.1365-2567.2011.03521.x
   PubMed Web of Science ®Google Scholar
• Veuillen C, Aurran-Schleinitz T, Castellano R, Rey J, Mallet F, Orlanducci F, Pouyet L, Just-Landi S, Coso D, Ivanov V et al. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol 2012; 32:632–46; PMID:22318393; https://doi.org/10.1007/s10875-011-9624-5
   PubMed Web of Science ®Google Scholar
• Parry HM, Stevens T, Oldreive C, Zadran B, McSkeane T, Rudzki Z, Paneesha S, Chadwick C, Stankovic T, Pratt G et al. NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma. Oncotarget 2016; 7:68513–26; PMID:27655680; https://doi.org/10.18632/oncotarget.12097
   PubMed Web of Science ®Google Scholar
• Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, Davi F, Debré P, Prost JF, Teillaud JL et al. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia 2011; 25:101–9; PMID:20975664; https://doi.org/10.1038/leu.2010.240
   PubMed Web of Science ®Google Scholar
• Lee J, Zhang T, Hwang I, Kim A, Nitschke L, Kim M, Scott JM, Kamimura Y, Lanier LL, Kim S. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 2015; 42:431–42; PMID:25786175; https://doi.org/10.1016/j.immuni.2015.02.013
   PubMed Web of Science ®Google Scholar
• Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, Holmes TD, Han H, Chiang SC, Foley B, Mattsson K et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 2015; 42:443–56; PMID:25786176; https://doi.org/10.1016/j.immuni.2015.02.008
   PubMed Web of Science ®Google Scholar
• Wlasiuk P, Tomczak W, Zajac M, Dmoszynska A, Giannopoulos K. Total expression of HLA-G and TLR-9 in chronic lymphocytic leukemia patients. Hum Immunol 2013; 74:1592–7; PMID:23994589; https://doi.org/10.1016/j.humimm.2013.08.277
   PubMed Web of Science ®Google Scholar
• Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005; 105:1694–8; PMID:15466928; https://doi.org/10.1182/blood-2004-08-3335
   PubMed Web of Science ®Google Scholar
• Buechele C, Baessler T, Wirths S, Schmohl JU, Schmiedel BJ, Salih HR. Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL). Leukemia 2012; 26:991–1000; PMID:22064350; https://doi.org/10.1038/leu.2011.313
   PubMed Web of Science ®Google Scholar
• Werlenius O, Aurelius J, Hallner A, Akhiani AA, Simpanen M, Martner A, Andersson PO, Hellstrand K, Thorén FB. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells. Oncotarget 2016; 7:32046–53; PMID:27097113; https://doi.org/10.18632/oncotarget.8769
   PubMed Web of Science ®Google Scholar
• Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004; 64:4664–9; PMID:15231679; https://doi.org/10.1158/0008-5472.CAN-03-2862
   PubMed Web of Science ®Google Scholar
• Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism. Blood 2007; 110:2561–4; PMID:17475906; https://doi.org/10.1182/blood-2007-01-070656
   PubMed Web of Science ®Google Scholar
• Wild J, Schmiedel BJ, Maurer A, Raab S, Prokop L, Stevanovic S, Dörfel D, Schneider P, Salih HR. Neutralization of (NK-cell-derived) B-cell activating factor by belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and rituximab-induced NK lysis. Leukemia 2015; 29:1676–83; PMID:25710310; https://doi.org/10.1038/leu.2015.50
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008; 14:4650–7; PMID:18628480; https://doi.org/10.1158/1078-0432.CCR-07-4405
   PubMed Web of Science ®Google Scholar
• Chavez JC, Piris-Villaespesa M, Dalia S, Powers J, Turba E, Nodzon L, Komrokji R, Sokol L, Locke FL, Lancet J et al. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leuk Res 2016; 47:78–83; PMID:27285853; https://doi.org/10.1016/j.leukres.2016.05.012
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rodriguez AP, Contesti J, Huergo-Zapico L, Lopez-Soto A, Fernandez-Guizan A, Acebes-Huerta A, Gonzalez-Huerta AJ, Gonzalez E, Fernandez-Alvarez C, Gonzalez S. Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. Leuk Lymphoma 2010; 51:1829–36; PMID:20846097; https://doi.org/10.3109/10428194.2010.503820/bib>
   PubMed Web of Science ®Google Scholar
• Huergo-Zapico L, Acebes-Huerta A, Gonzalez-Rodriguez AP, Contesti J, Gonzalez-Garcia E, Payer AR, Villa-Alvarez M, Fernández-Guizán A, López-Soto A, Gonzalez S. Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease. PLoS One 2014; 9:e108326; PMID:25286418; https://doi.org/10.1371/journal.pone.0108326
   PubMed Web of Science ®Google Scholar
• Palmer S, Hanson CA, Zent CS, Porrata LF, Laplant B, Geyer SM, Markovic SN, Call TG, Bowen DA, Jelinek DF et al. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol 2008; 141:607–14; PMID:18384436; https://doi.org/10.1111/j.1365-2141.2008.07070.x
   PubMed Web of Science ®Google Scholar
• Caligiuri MA. Human natural killer cells. Blood 2008; 112:461–9; PMID:18650461; https://doi.org/10.1182/blood-2007-09-077438
   PubMed Web of Science ®Google Scholar
• Silva A, Andrews DM, Brooks AG, Smyth MJ, Hayakawa Y. Application of CD27 as a marker for distinguishing human NK cell subsets. Int Immunol 2008; 20:625–30; PMID:18326863; https://doi.org/10.1093/intimm/dxn022
   PubMed Web of Science ®Google Scholar
• Vossen MT, Matmati M, Hertoghs KM, Baars PA, Gent MR, Leclercq G, Hamann J, Kuijpers TW, van Lier RA. CD27 defines phenotypically and functionally different human NK cell subsets. J Immunol 2008; 180:3739–45; PMID:18322179; https://doi.org/10.4049/jimmunol.180.6.3739
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Schmitt M, Kowal M, Wlasiuk P, Bojarska-Junak A, Chen J, Rolinski J, Dmoszynska A. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncology Rep 2008; 20:677–82; PMID:18695923; https://doi.org/10.3892/or_00000059
   PubMed Web of Science ®Google Scholar
• Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294:15–22; PMID:15604012; https://doi.org/10.1016/j.jim.2004.08.008
   PubMed Web of Science ®Google Scholar
• Bryceson YT, Fauriat C, Nunes JM, Wood SM, Bjorkstrom NK, Long EO, Ljunggren HG. Functional analysis of human NK cells by flow cytometry. Methods Mol Biol 2010; 612:335–52; PMID:20033652; https://doi.org/10.1007/978-1-60761-362-6_23
   PubMedGoogle Scholar
• Eischen CM, Schilling JD, Lynch DH, Krammer PH, Leibson PJ. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 1996; 156:2693–9; PMID:8609385.
   PubMed Web of Science ®Google Scholar
• Jewett A, Cavalcanti M, Giorgi J, Bonavida B. Concomitant killing in vitro of both gp120-coated CD4+ peripheral T lymphocytes and natural killer cells in the antibody-dependent cellular cytotoxicity (ADCC) system. J Immunol 1997; 158:5492–500; PMID:9164972.
   PubMed Web of Science ®Google Scholar
• Warren H. Target-induced natural killer cell loss as a measure of NK cell responses. Curr Protocols Immunol 2013; Chapter 14.29.1-21; PMID:23564684; https://doi.org/10.1002/0471142735.im1429s101.
   PubMedGoogle Scholar
• Poggi A, Massaro AM, Negrini S, Contini P, Zocchi MR. Tumor-induced apoptosis of human IL-2-activated NK cells: role of natural cytotoxicity receptors. J Immunol 2005; 174:2653–60; PMID:15728472; https://doi.org/10.4049/jimmunol.174.5.2653
   PubMed Web of Science ®Google Scholar
• Purdy AK, Campbell KS. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther 2009; 8:2211–20; PMID:19923897; https://doi.org/10.4161/cbt.8.23.10455
   PubMed Web of Science ®Google Scholar
• Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 1995; 85:3556–65; PMID:7540066.
   PubMed Web of Science ®Google Scholar
• Jang YS, Kang W, Chang DY, Sung PS, Park BC, Yoo SH, Park YW, Shin EC. CD27 engagement by a soluble CD70 protein enhances non-cytolytic antiviral activity of CD56bright natural killer cells by IFN-gamma secretion. Clin Immunol 2013; 149:379–87; PMID:24211844; https://doi.org/10.1016/j.clim.2013.09.007
   PubMed Web of Science ®Google Scholar
• Jenkins MR, Rudd-Schmidt JA, Lopez JA, Ramsbottom KM, Mannering SI, Andrews DM, Voskoboinik I, Trapani JA. Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med 2015; 212:307–17; PMID:25732304; https://doi.org/10.1084/jem.20140964
   PubMed Web of Science ®Google Scholar
• Rojas R, Roman J, Torres A, Ramirez R, Carracedo J, Lopez R, Garcia JM, Martin C, Pintado O. Inhibition of apoptotic cell death in B-CLL by interferon gamma correlates with clinical stage. Leukemia 1996; 10:1782–8; PMID:8892682.
   PubMed Web of Science ®Google Scholar
• Zaki M, Douglas R, Patten N, Bachinsky M, Lamb R, Nowell P, Moore J. Disruption of the IFN-gamma cytokine network in chronic lymphocytic leukemia contributes to resistance of leukemic B cells to apoptosis. Leuk Res 2000; 24:611–21; PMID:10867137; https://doi.org/10.1016/S0145-2126(00)00022-9
   PubMed Web of Science ®Google Scholar
• Reiners KS, Topolar D, Henke A, Simhadri VR, Kessler J, Sauer M, Bessler M, Hansen HP, Tawadros S, Herling M et al. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood 2013; 121:3658–65; PMID:23509156; https://doi.org/10.1182/blood-2013-01-476606
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370:1101–10; PMID:24401022; https://doi.org/10.1056/NEJMoa1313984
   PubMed Web of Science ®Google Scholar
• Nuckel H, Switala M, Sellmann L, Horn PA, Durig J, Duhrsen U, Küppers R, Grosse-Wilde H, Rebmann V. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 2010; 24:1152–9; PMID:20428196; https://doi.org/10.1038/leu.2010.74
   PubMed Web of Science ®Google Scholar
• Hilpert J, Grosse-Hovest L, Grunebach F, Buechele C, Nuebling T, Raum T, Steinle A, Salih HR. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 2012; 189:1360–71; PMID:22730533; https://doi.org/10.4049/jimmunol.1200796
   PubMed Web of Science ®Google Scholar
• Nakamura K, Nakayama M, Kawano M, Amagai R, Ishii T, Harigae H, Ogasawara K. Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand. Proc Natl Acad Sci USA 2013; 110:9421–6; PMID:23690625; https://doi.org/10.1073/pnas.1300140110
   PubMed Web of Science ®Google Scholar
• Shifrin N, Raulet DH, Ardolino M. NK cell self-tolerance, responsiveness and missing self-recognition. Semin Immunol 2014; 26:138–44; PMID:24629893; https://doi.org/10.1016/j.smim.2014.02.007
   PubMed Web of Science ®Google Scholar
• McWilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ, Mo X, Byrd JC, Muthusamy N, Awan FT. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology 2016; 5:e1226720; PMID:27853650; https://doi.org/10.1080/2162402X.2016.1226720
   PubMed Web of Science ®Google Scholar
• Mentlik James A, Cohen AD, Campbell KS. Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol 2013; 4:481; PMID:24391651; https://doi.org/10.3389/fimmu.2013.00481
   PubMed Web of Science ®Google Scholar
• Ardolino M, Azimi CS, Iannello A, Trevino TN, Horan L, Zhang L, Deng W, Ring AM, Fischer S, Garcia KC et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest 2014; 124:4781–94; PMID:25329698; https://doi.org/10.1172/JCI74337
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Nederby L, Thysen AH, Skovbo A, Roug AS, Hokland ME. Interleukin-21 and rituximab enhance NK cell functionality in patients with B-cell chronic lymphocytic leukaemia. Leuk Res 2011; 35:914–20; PMID:21354618; https://doi.org/10.1016/j.leukres.2011.02.006
   PubMed Web of Science ®Google Scholar
• Laprevotte E, Voisin G, Ysebaert L, Klein C, Daugrois C, Laurent G, Fournie JJ, Quillet-Mary A. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy. J Immunol 2013; 191:3634–40; PMID:23997218; https://doi.org/10.4049/jimmunol.1300187
   PubMed Web of Science ®Google Scholar
• MacFarlane AW IV, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E, Al-Saleem T, Campbell KS. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res 2014; 2:320–31; PMID:24764579; https://doi.org/10.1158/2326-6066.CIR-13-0133
   PubMed Web of Science ®Google Scholar
• Czaja K, Borer AS, Schmied L, Terszowski G, Stern M, Gonzalez A. A comprehensive analysis of the binding of anti-KIR antibodies to activating KIRs. Genes Immun 2014; 15:33–7; PMID:24173145; https://doi.org/10.1038/gene.2013.58
   PubMed Web of Science ®Google Scholar